Eli Lilly’s Jaypirca (pirtobrutinib) has been approved in the US for lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL). It has been granted approval by the Food and Drug Administration (FDA) to treat patients who have received at least two lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor. The decision […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!